An observational study in Depressive Disorder, Major, Generalized Anxiety Disorder and Suicidal Ideation, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Depressive Disorder, Major with a site in France — 28 open to participants now, 31 under way, 2 of them phase 3. Depressive Disorder, Major · France.
Among the 127 studies in Depressive Disorder, Major with a site in France, this one has the largest planned enrollment of the 21 observational ones that give a count, is one of 7 that started in 2026, is one of 21 observational ones, reaches primary completion later than 25 of the 30 other live ones, and was the 124th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →28 of the 127 studies in Depressive Disorder, Major with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18–65 · Healthy volunteers
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Hospital Center Guillaume Régnier · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18–54 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 37 · Phase 4 10
First in 2003; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45,000 is above the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.
Median enrollment 232 across the 106 interventional studies, 128 across the 21 observational. Of the 84 that completed or were terminated, 31 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 127 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 7 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
8 of the studies in Depressive Disorder, Major with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07316803Centre hospitalier de Ville-Evrard, FranceGroup Intervention for Romantic Relationships in Young Adults With Severe Mental Illness | 2026-11-30 |
| NCT06234176Centre Hospitalier EsquirolImpact of Psychomotor Therapy on the Quality of Life in Depression | 2027-02 |
| NCT06601140EmobotEvaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode | 2027-02-04 |
| NCT06732284Centre Hospitalier Universitaire de NīmesStudy of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance Task | 2027-03 |
Add all 8 to your calendar (.ics) → With an account.
Among the 127 studies in Depressive Disorder, Major with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Since the COVID-19 pandemic, mental health disorders have increased significantly, particularly among young people. In France, the proportion of young people aged 18 to 25 suffering from depression almost doubled between 2017 and 2021. This phenomenon particularly affects students, who are already identified as being at greater risk of mental health disorders than the general population. Medical students seem to be particularly vulnerable: in 2021, a national study showed very high rates of depression and suicidal thoughts in this population. The main factor associated with depression was the feeling of financial hardship.
Students often face multiple forms of insecurity. Financially, they have limited resources and struggle to cover their basic needs such as housing, food and healthcare. Socially, many experience significant isolation, particularly when they are away from their families or under pressure from their studies. All of this has a significant impact on their mental health. Unfortunately, many students do not seek help due to lack of time, resources, or awareness of support services. The 2021 study showed that only one-third of medical students suffering from depression received appropriate treatment.
The aim of our study is to assess the impact of precariousness on the onset of psychiatric disorders and on the use or non-use of healthcare services.
Our study will involve nearly 45,000 students from PSL and UPC universities. It is based on a longitudinal cohort (via questionnaires) over three years. The aim is to identify precisely the different aspects of student precariousness (housing, transport, isolation, economic difficulties, etc.) and their link with psychological distress. The study will measure the extent of the phenomenon and identify modifiable factors that could be targeted by preventive measures. The results will enable us to better target preventive measures and propose concrete solutions to improve students' well-being and promote their success.
The COVID-19 pandemic has led to an increase in depression, particularly among young people. The French health barometer, conducted every 4-5 years by Santé Publique France (SPF), found that the prevalence of major depressive episodes (MDE) among 18-25 year olds doubled (from 11.7% to 20.8%) between 2017 and 2021. There has also been an increase in suicidal thoughts and suicide attempts. Among students, data from the 2016 Student Life Observatory (OVE) found a higher prevalence of CDE and suicidal thoughts among students than in the general population of the same age. Among the factors associated with the risk of EDC, experiencing significant financial difficulties was the main one[4]. Among medical students, a national study conducted in 2021 found that the prevalence of depression and suicidal thoughts was much higher than in the general population of the same age. Financial difficulties were also the main factor associated with the risk of depression. Indeed, students are a population that is particularly vulnerable to precariousness due to several factors. Economically, they often have limited incomes, depending on parental support, insufficient grants or precarious jobs. This exposes them to difficulties in meeting their basic needs such as housing, food and healthcare. Socially, isolation can exacerbate their situation, especially when they are far from their family network or under pressure from their studies. In addition, high academic demands, combined with unstable living conditions, impact their mental health and can contribute to the development of psychiatric disorders, which often go untreated due to a lack of affordable and accessible resources. International students are even more vulnerable due to language and administrative barriers and limited access to local support services. This multidimensional precariousness highlights the need for comprehensive support for this population, even though students are unlikely to seek professional help. In the 2021 survey, only 32% of medical students suffering from depression received adequate care. If we want to improve the health of medical students, we must not only treat disorders, but also prevent them from occurring by helping students strive for a state of well-being. In terms of prevention, the Haute Autorité de Santé (HAS) distinguishes between three levels: primary prevention, which acts upstream of the disease (on risk factors); secondary prevention, which acts at an early stage of its development (screening); and tertiary prevention, which acts on complications and the risk of recurrence.
The objectives of the study are to identify and quantify the modifiable predictive and moderating factors explaining students' psychological distress that could give rise to (primary) prevention actions by studying the various components of precariousness (housing, transport, study conditions, social isolation, grants, etc.). It also aims to study the impact of the various components of precariousness on the use and non-use of healthcare (screening and treatment, secondary and tertiary prevention).
The data will be entered directly by participants on the SKEZIA platform (https://skezi.eu/) (a solution developed by SKEZI) co-founded by AP-HP and Paris-Cité University, and will be hosted on HDS-approved servers.
Main objective:
The objective is to explore the impact of precariousness on the risk of characterised depressive episodes and the use of healthcare among PSL students (17,000 students) and UPC health faculty students (28,000 students).
Primary outcome measure:
The study will assess the 12-month prevalence of:
Precariousness will be assessed by the question: 'Would you say that you are currently experiencing financial difficulties?'
Secondary objectives and evaluation criteria:
The secondary objectives are to :
All students enrolled at Paris Sciences et Lettres University or the Faculty of Health Sciences at Paris Cité University.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All students enrolled at the Faculty of Health Sciences of Paris Cité University
Other: Questionnaires
All students enrolled at Paris Sciences and Letters University
Other: Questionnaires
Questionnaires
Composite International Diagnostic Interview Short-Form (CIDI-SF)
12-months prevalence Major Depressive Disorder and suicidal thoughts Composite International Diagnostic Interview Short-Form (CIDI-SF)
Time frame: Day 0
Composite International Diagnostic Interview Short-Form (CIDI-SF)
12-months prevalence Major Depressive Disorder and suicidal thoughts Composite International Diagnostic Interview Short-Form (CIDI-SF)
Time frame: 12 months
Use of care
Use of care service of care professional
Time frame: Day 0
Use of care
Use of care service of care professional
Time frame: 12 months
Precarity
Question "Would you say that you are currently experiencing financial difficulties?"
Time frame: Day 0
Precarity
Question "Would you say that you are currently experiencing financial difficulties?"
Time frame: 12 months
GAD7
Prevalence of anxiety
Time frame: Day 0
GAD7
Prevalence of anxiety
Time frame: 12 months
GAD7
Prevalence of anxiety
Time frame: 24 months
SCOFF
Prevalence of Eating disorders
Time frame: Day 0
SCOFF
Prevalence of Eating disorders
Time frame: 12 months
SCOFF
Prevalence of Eating disorders
Time frame: 24 months
AUDIT
Prevalence of Alcohol addiction
Time frame: Day 0
AUDIT
Prevalence of Alcohol addiction
Time frame: 12 months
AUDIT
Prevalence of Alcohol addiction
Time frame: 24 months
CAST
Prevalence of cannabis addiction
Time frame: Day 0
CAST
Prevalence of cannabis addiction
Time frame: 12 months
CAST
Prevalence of cannabis addiction
Time frame: 24 months
MBI-SS or MBI-HSS
Prevalence of Burnout using the student version : will be assessed using the MBI-SS for pre-clinical students or caregivers or Prevalence of Burnout using the student version : will be assessed using the MBI-HSS for externs and residents
Time frame: Day 0
MBI-SS or MBI-HSS
Prevalence of Burnout using the student version : will be assessed using the MBI-SS for pre-clinical students or caregivers or Prevalence of Burnout using the student version : will be assessed using the MBI-HSS for externs and residents Time Frame: D0
Time frame: 12 months
MBI-SS or MBI-HSS
Prevalence of Burnout using the student version : will be assessed using the MBI-SS for pre-clinical students or caregivers or Prevalence of Burnout using the student version : will be assessed using the MBI-HSS for externs and residents Time Frame: D0
Time frame: 24 months
A single question as in the CNA-CORE survey
Prevalence of Dropout: will be assessed using a single question as in the CNA-CORE survey
Time frame: Day 0
A single question as in the CNA-CORE survey
Prevalence of Dropout: will be assessed using a single question as in the CNA-CORE survey
Time frame: 12 months
A single question as in the CNA-CORE survey
Prevalence of Dropout: will be assessed using a single question as in the CNA-CORE survey
Time frame: 24 months
Insomnia Severity Index (ISI)
Prevalence of Insomnia
Time frame: Day 0
Insomnia Severity Index (ISI)
Prevalence of Insomnia
Time frame: 12 months
Insomnia Severity Index (ISI)
Prevalence of Insomnia
Time frame: 24 months
UCLA 3 items
Prevalence of Loneliness
Time frame: Day 0
UCLA 3 items
Prevalence of Loneliness
Time frame: 12 months
UCLA 3 items
Prevalence of Loneliness
Time frame: 24 months
Questions about harrassment
Harrassment
Time frame: Day 0
Questions about harrassment
Harrassment
Time frame: 12 months
Questions about harrassment
Harrassment
Time frame: 24 months
Questions about discriminatory treatment
Discriminatory treatment
Time frame: Day 0
Questions about discriminatory treatment
Discriminatory treatment
Time frame: 12 months
Questions about discriminatory treatment
Discriminatory treatment
Time frame: 24 months
WHOQOL
Quality of life
Time frame: Day 0
WHOQOL
Quality of life
Time frame: 12 months
WHOQOL
Quality of life
Time frame: 24 months
Components of precariousness
Predictive and moderating factors = by studying the different components of precariousness (housing, transport, study conditions, social isolation, grants, etc.).
Time frame: Day 0
Components of precariousness
Predictive and moderating factors = by studying the different components of precariousness (housing, transport, study conditions, social isolation, grants, etc.).
Time frame: 12 months
Questions on the renunciation of healthcare and its causes.
Impact of the various components of precariousness on the use and non-use of healthcare will be assessed using questions on the renunciation of healthcare and its causes.
Time frame: 12 months
Components of precariousness
Predictive and moderating factors = by studying the different components of precariousness (housing, transport, study conditions, social isolation, grants, etc.).
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.
Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 24 months is below that.
Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Sep 2026 → Oct 2026, primary completion Sep 2028 → Oct 2028 and completion Nov 2028 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →